You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOlopatadine
Accession NumberDB00768  (APRD00310)
TypeSmall Molecule
GroupsApproved
DescriptionUsed to treat allergic conjunctivitis (itching eyes), olopatadine inhibits the release of histamine from mast cells. It is a relatively selective histamine H1 antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells.
Structure
Thumb
Synonyms
Olopatadin
Olopatadina
Olopatadine
Olopatadinum
Opatanol
External Identifiers
  • ALO 4943 A
  • KW 4679
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Olopatadine 0.1%solution0.1 %ophthalmicActavis Pharma Company2013-12-06Not applicableCanada
Act Olopatadine 0.2%solution0.2 %ophthalmicActavis Pharma Company2014-02-20Not applicableCanada
Mint-olopatadinesolution0.1 %ophthalmicMint Pharmaceuticals Inc2014-07-29Not applicableCanada
Olopatadine Hydrochloridespray, metered665 ug/100uLnasalFalcon Pharmaceuticals, Ltd.2012-06-30Not applicableUs
Olopatadine Hydrochloridesolution/ drops1 mg/mLophthalmicSandoz Inc.2015-09-15Not applicableUs
Olopatadine Hydrochloride Nasalspray665 ug/1nasalPerrigo New York Inc2015-04-01Not applicableUs
Olopatadine Ophthalmic Solutionsolution0.1 %ophthalmicBeximco Pharmaceuticals Canada LimitedNot applicableNot applicableCanada
Patadaysolution/ drops2 mg/mLophthalmicLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-04-03Not applicableUs
Patadaysolution/ drops2 mg/mLophthalmicPhysicians Total Care, Inc.2011-01-03Not applicableUs
Patadaysolution/ drops2 mg/mLophthalmicAlcon Laboratories, Inc.2007-02-15Not applicableUs
Patadaysolution0.2 %ophthalmicAlcon Canada Inc2011-04-14Not applicableCanada
Patanasespray, metered665 ug/1nasalPhysicians Total Care, Inc.2009-07-13Not applicableUs
Patanasespray, metered665 ug/1nasalClinical Solutions Wholesale2008-04-28Not applicableUs
Patanasespray, metered600 ug/1nasalAlcon Laboratories, Inc.2008-04-28Not applicableUs
Patanolsolution/ drops1 mg/mLophthalmicAlcon Laboratories, Inc.1997-02-17Not applicableUs
Patanolsolution/ drops1 mg/mLophthalmicPhysicians Total Care, Inc.2002-05-08Not applicableUs
Patanol Ophthalmic Solutionliquid0.1 %ophthalmicAlcon Canada Inc1998-02-09Not applicableCanada
Pazeosolution7 mg/mLophthalmicAlcon Laboratories, Inc.2015-01-29Not applicableUs
Sandoz Olopatadinesolution0.1 %ophthalmicSandoz Canada Incorporated2013-02-04Not applicableCanada
Sandoz Olopatadine 0.2%solution0.2 %ophthalmicSandoz Canada Incorporated2014-02-24Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-olopatadinesolution0.2 %ophthalmicApotex Inc2014-04-10Not applicableCanada
Apo-olopatadinesolution0.1 %ophthalmicApotex Inc2013-07-26Not applicableCanada
Olopatadine Hydrochloridesolution/ drops1.11 mg/mLophthalmicNovel Laboratories, Inc.2015-12-07Not applicableUs
Olopatadine Hydrochloridesolution/ drops1 mg/mLophthalmicRising Pharmaceuticals, Inc.2015-12-07Not applicableUs
Olopatadine Hydrochloridesolution/ drops1 mg/mLophthalmicAlvogen Inc.2015-12-08Not applicableUs
Olopatadine Hydrochloridesolution/ drops1 mg/mLophthalmicAurobindo Pharma Limited2015-12-18Not applicableUs
Olopatadine Hydrochloridesolution/ drops1 mg/mLophthalmicApotex Corp.2015-12-07Not applicableUs
Olopatadine Hydrochloridespray, metered665 ug/1nasalApotex Corp.2014-10-27Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AlchekApex
AlerchekIndoco
AllelockDae Woong
OpatanolAlcon
Patanol SAlcon
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Olopatadine Hydrochloride
Thumb
  • InChI Key: HVRLZEKDTUEKQH-NOILCQHBSA-N
  • Monoisotopic Mass: 373.144471346
  • Average Mass: 373.873
DBSALT000685
Categories
UNIID27V6190PM
CAS number113806-05-6
WeightAverage: 337.4122
Monoisotopic: 337.167793607
Chemical FormulaC21H23NO3
InChI KeyInChIKey=JBIMVDZLSHOPLA-LSCVHKIXSA-N
InChI
InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8-
IUPAC Name
2-[(2Z)-2-[3-(dimethylamino)propylidene]-9-oxatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3(8),4,6,11,13-hexaen-5-yl]acetic acid
SMILES
CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzoxepines. These are compounds containing a dibenzoxepine moiety, which consists of two benzene connected by an oxazepine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzoxepines
Sub ClassDibenzoxepines
Direct ParentDibenzoxepines
Alternative Parents
Substituents
  • Dibenzoxepine
  • Alkyl aryl ether
  • Benzenoid
  • Tertiary aliphatic amine
  • Tertiary amine
  • Oxacycle
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of ocular itching associated with allergic conjunctivitis.
PharmacodynamicsUsed to treat allergic conjunctivitis (itching eyes), olopatadine inhibits the release of histamine from mast cells. It is a relatively selective histamine H1 antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells.
Mechanism of actionOlopatadine is a selective histamine H1 antagonist that binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Olopatadine is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors.
Related Articles
AbsorptionOphthalmic use of olopatadine usually does not produce measurable plasma concentrations.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

The mono-desmethyl and the N-oxide metabolites have been detected at low concentrations in the urine.

SubstrateEnzymesProduct
Olopatadine
Not Available
Mono-desmethyl olopatadineDetails
Olopatadine
Not Available
Olopatadine n-oxideDetails
Route of eliminationElimination was predominantly through renal excretion.
Half life3 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9747
Blood Brain Barrier+0.6925
Caco-2 permeable+0.7249
P-glycoprotein substrateSubstrate0.8607
P-glycoprotein inhibitor IInhibitor0.5948
P-glycoprotein inhibitor IINon-inhibitor0.8196
Renal organic cation transporterInhibitor0.5413
CYP450 2C9 substrateNon-substrate0.7691
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7242
CYP450 1A2 substrateInhibitor0.7906
CYP450 2C9 inhibitorNon-inhibitor0.8316
CYP450 2D6 inhibitorInhibitor0.6567
CYP450 2C19 inhibitorNon-inhibitor0.8466
CYP450 3A4 inhibitorNon-inhibitor0.8222
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8676
Ames testNon AMES toxic0.8032
CarcinogenicityNon-carcinogens0.8499
BiodegradationNot ready biodegradable0.6088
Rat acute toxicity2.7626 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8082
hERG inhibition (predictor II)Inhibitor0.5
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Alcon inc
  • Alcon laboratories inc
  • Alcon Laboratories, Inc.
Packagers
Dosage forms
FormRouteStrength
Solutionophthalmic0.1 %
Solution/ dropsophthalmic1.11 mg/mL
Spray, meterednasal665 ug/100uL
Spraynasal665 ug/1
Solutionophthalmic0.2 %
Solution/ dropsophthalmic2 mg/mL
Spray, meterednasal600 ug/1
Spray, meterednasal665 ug/1
Solution/ dropsophthalmic1 mg/mL
Liquidophthalmic0.1 %
Solutionophthalmic7 mg/mL
Prices
Unit descriptionCostUnit
Patanol 0.1% Solution 5ml Bottle111.2USD bottle
Pataday 0.2% eye drops52.98USD ml
Patanol 0.1% eye drops21.38USD ml
Patanase 0.6% nasal spray3.83USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1337603 No1995-11-212012-11-21Canada
CA2195094 No2002-02-262016-05-03Canada
US5116863 No1993-12-182010-12-18Us
US5641805 Yes1995-12-062015-12-06Us
US6995186 Yes2004-05-122024-05-12Us
US7402609 Yes2002-12-192022-12-19Us
US7977376 Yes2003-08-022023-08-02Us
US8399508 Yes2003-03-172023-03-17Us
US8791154 No2012-05-192032-05-19Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point248 °CNot Available
water solubilitySolubleNot Available
logP3.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0313 mg/mLALOGPS
logP3.99ALOGPS
logP0.75ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)3.78ChemAxon
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area49.77 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity109.55 m3·mol-1ChemAxon
Polarizability37.44 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Thomas Bader, Hans-Ulrich Bichsel, Bruno Gilomen, Imelda Meyer-Wilmes, Mark Sundermeier, “Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof.” U.S. Patent US20070232814, issued October 04, 2007.

US20070232814
General References
  1. Ohmori K, Hayashi K, Kaise T, Ohshima E, Kobayashi S, Yamazaki T, Mukouyama A: Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol. 2002 Apr;88(4):379-97. [PubMed:12046981 ]
  2. Yanni JM, Stephens DJ, Miller ST, Weimer LK, Graff G, Parnell D, Lang LS, Spellman JM, Brady MT, Gamache DA: The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther. 1996 Winter;12(4):389-400. [PubMed:8951675 ]
  3. Ohmori K, Hasegawa K, Tamura T, Miyake K, Matsubara M, Masaki S, Karasawa A, Urayama N, Horikoshi K, Kajita J, Hasegawa M, Taniguchi K, Komada T, Kawamoto Y: Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug. Arzneimittelforschung. 2004;54(12):809-29. [PubMed:15646365 ]
  4. Ohmori K, Ikemura T, Kobayashi H, Mukouyama A: [Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride' (olopatadine), an antiallergic drug]. Nihon Yakurigaku Zasshi. 2001 Jul;118(1):51-8. [PubMed:11496828 ]
  5. Kaliner MA, Oppenheimer J, Farrar JR: Comprehensive review of olopatadine: the molecule and its clinical entities. Allergy Asthma Proc. 2010 Mar-Apr;31(2):112-9. doi: 10.2500/aap.2010.31.3317. [PubMed:20406593 ]
External Links
ATC CodesS01GX09R01AC08
AHFS Codes
  • 04:00.00
PDB EntriesNot Available
FDA labelDownload (114 KB)
MSDSDownload (57.6 KB)
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Olopatadine.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Olopatadine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Olopatadine.
AbciximabOlopatadine may increase the anticoagulant activities of Abciximab.
AcebutololOlopatadine may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Olopatadine is combined with Aceclofenac.
AcenocoumarolOlopatadine may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Olopatadine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Olopatadine.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Acetylsalicylic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Olopatadine.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Olopatadine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Olopatadine.
Alendronic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Alendronic acid.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Olopatadine.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Olopatadine.
AliskirenOlopatadine may decrease the antihypertensive activities of Aliskiren.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Olopatadine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Olopatadine.
AlprenololOlopatadine may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Olopatadine.
AmikacinOlopatadine may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideOlopatadine may decrease the antihypertensive activities of Amiloride.
AmiodaroneThe metabolism of Olopatadine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Olopatadine.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Olopatadine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Olopatadine.
AmoxapineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Olopatadine.
AmphetamineAmphetamine may decrease the sedative activities of Olopatadine.
AncrodOlopatadine may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Antipyrine.
Antithrombin III humanOlopatadine may increase the anticoagulant activities of Antithrombin III human.
ApixabanOlopatadine may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Olopatadine is combined with Apremilast.
AprepitantThe serum concentration of Olopatadine can be increased when it is combined with Aprepitant.
ArdeparinOlopatadine may increase the anticoagulant activities of Ardeparin.
ArgatrobanOlopatadine may increase the anticoagulant activities of Argatroban.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Olopatadine.
ArotinololOlopatadine may decrease the antihypertensive activities of Arotinolol.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Olopatadine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Olopatadine.
AtazanavirThe metabolism of Olopatadine can be decreased when combined with Atazanavir.
AtenololOlopatadine may decrease the antihypertensive activities of Atenolol.
AtomoxetineThe metabolism of Olopatadine can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Olopatadine.
AzapropazoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Azapropazone.
AzelastineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Olopatadine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Olopatadine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Olopatadine.
BalsalazideOlopatadine may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Olopatadine.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Olopatadine.
BecaplerminOlopatadine may increase the anticoagulant activities of Becaplermin.
BefunololOlopatadine may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Olopatadine.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Olopatadine.
BenoxaprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Benoxaprofen.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Olopatadine.
BenzphetamineBenzphetamine may decrease the sedative activities of Olopatadine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Olopatadine.
Benzylpenicilloyl PolylysineOlopatadine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Olopatadine.
BetaxololOlopatadine may decrease the antihypertensive activities of Betaxolol.
BevantololOlopatadine may decrease the antihypertensive activities of Bevantolol.
BexaroteneThe serum concentration of Olopatadine can be decreased when it is combined with Bexarotene.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Olopatadine.
BisoprololOlopatadine may decrease the antihypertensive activities of Bisoprolol.
BivalirudinOlopatadine may increase the anticoagulant activities of Bivalirudin.
BoceprevirThe metabolism of Olopatadine can be decreased when combined with Boceprevir.
BopindololOlopatadine may decrease the antihypertensive activities of Bopindolol.
BortezomibThe metabolism of Olopatadine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Olopatadine can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Olopatadine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.
BrimonidineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Olopatadine.
BromfenacThe risk or severity of adverse effects can be increased when Olopatadine is combined with Bromfenac.
BrompheniramineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Olopatadine.
BufuralolOlopatadine may decrease the antihypertensive activities of Bufuralol.
BumetanideOlopatadine may decrease the diuretic activities of Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Olopatadine.
BupranololOlopatadine may decrease the antihypertensive activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Olopatadine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Olopatadine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Olopatadine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Olopatadine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Olopatadine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Olopatadine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Olopatadine.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Olopatadine.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Olopatadine.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Olopatadine.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Olopatadine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Olopatadine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Olopatadine.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Olopatadine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Olopatadine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Olopatadine.
CarprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Carprofen.
CarteololOlopatadine may decrease the antihypertensive activities of Carteolol.
CarvedilolOlopatadine may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Olopatadine.
CeliprololOlopatadine may decrease the antihypertensive activities of Celiprolol.
CeritinibThe serum concentration of Olopatadine can be increased when it is combined with Ceritinib.
CertoparinOlopatadine may increase the anticoagulant activities of Certoparin.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Olopatadine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Olopatadine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Olopatadine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Olopatadine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Olopatadine.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Olopatadine.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Olopatadine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Chlorphenamine.
ChlorphentermineChlorphentermine may decrease the sedative activities of Olopatadine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Olopatadine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Olopatadine.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Olopatadine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Olopatadine.
CholestyramineCholestyramine can cause a decrease in the absorption of Olopatadine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Olopatadine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Olopatadine.
CitalopramThe risk or severity of adverse effects can be increased when Olopatadine is combined with Citalopram.
Citric AcidOlopatadine may increase the anticoagulant activities of Citric Acid.
ClarithromycinThe metabolism of Olopatadine can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Olopatadine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Olopatadine.
ClodronateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clodronate.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Olopatadine.
ClomipramineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Olopatadine.
ClonixinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Olopatadine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Olopatadine.
ClotrimazoleThe metabolism of Olopatadine can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Olopatadine.
CobicistatThe metabolism of Olopatadine can be decreased when combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Olopatadine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Olopatadine.
ColesevelamColesevelam can cause a decrease in the absorption of Olopatadine resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Olopatadine resulting in a reduced serum concentration and potentially a decrease in efficacy.
ConivaptanThe serum concentration of Olopatadine can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Olopatadine can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Olopatadine.
CyclosporineOlopatadine may increase the nephrotoxic activities of Cyclosporine.
CyclosporineThe metabolism of Olopatadine can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Olopatadine.
D-LimoneneThe risk or severity of adverse effects can be increased when Olopatadine is combined with D-Limonene.
Dabigatran etexilateOlopatadine may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Olopatadine can be decreased when it is combined with Dabrafenib.
DalteparinOlopatadine may increase the anticoagulant activities of Dalteparin.
DanaparoidOlopatadine may increase the anticoagulant activities of Danaparoid.
DantroleneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Olopatadine.
DapoxetineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dapoxetine.
DarunavirThe metabolism of Olopatadine can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Olopatadine can be increased when it is combined with Dasatinib.
DaunorubicinOlopatadine may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe serum concentration of Olopatadine can be decreased when it is combined with Deferasirox.
DeferasiroxThe risk or severity of adverse effects can be increased when Olopatadine is combined with Deferasirox.
DelavirdineThe metabolism of Olopatadine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Olopatadine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Olopatadine.
DesipramineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desipramine.
DesirudinOlopatadine may increase the anticoagulant activities of Desirudin.
DesloratadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desloratadine.
DesmopressinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desmopressin.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Olopatadine.
DexamethasoneThe serum concentration of Olopatadine can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Olopatadine.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Olopatadine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Olopatadine.
DextranOlopatadine may increase the anticoagulant activities of Dextran.
Dextran 40Olopatadine may increase the anticoagulant activities of Dextran 40.
Dextran 70Olopatadine may increase the anticoagulant activities of Dextran 70.
Dextran 75Olopatadine may increase the anticoagulant activities of Dextran 75.
DextroamphetamineDextroamphetamine may decrease the sedative activities of Olopatadine.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Olopatadine.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Olopatadine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Olopatadine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Olopatadine.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Olopatadine.
DicoumarolOlopatadine may increase the anticoagulant activities of Dicoumarol.
DifenoxinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Difenoxin.
DiflunisalThe risk or severity of adverse effects can be increased when Olopatadine is combined with Diflunisal.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Olopatadine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Olopatadine.
DihydroergotamineThe metabolism of Olopatadine can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Olopatadine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Olopatadine.
DihydrostreptomycinOlopatadine may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DiltiazemThe metabolism of Olopatadine can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dimenhydrinate.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Olopatadine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Olopatadine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Olopatadine.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Olopatadine.
DoxepinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Doxepin.
DoxorubicinOlopatadine may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DoxycyclineThe metabolism of Olopatadine can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.
DoxylamineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Olopatadine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.
DronedaroneThe metabolism of Olopatadine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Olopatadine.
DrospirenoneOlopatadine may increase the hyperkalemic activities of Drospirenone.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Olopatadine.
DroxicamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Droxicam.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Olopatadine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Olopatadine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Olopatadine.
Edetic AcidOlopatadine may increase the anticoagulant activities of Edetic Acid.
EdoxabanOlopatadine may increase the anticoagulant activities of Edoxaban.
EfavirenzThe serum concentration of Olopatadine can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Olopatadine is combined with Efavirenz.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Olopatadine.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Olopatadine.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Olopatadine.
EnoxaparinOlopatadine may increase the anticoagulant activities of Enoxaparin.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Olopatadine.
EnzalutamideThe serum concentration of Olopatadine can be decreased when it is combined with Enzalutamide.
EpirizoleThe risk or severity of adverse effects can be increased when Olopatadine is combined with Epirizole.
EpirubicinOlopatadine may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneOlopatadine may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Olopatadine.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Olopatadine.
ErythromycinThe metabolism of Olopatadine can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Olopatadine is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Olopatadine can be decreased when it is combined with Eslicarbazepine acetate.
EsmololOlopatadine may decrease the antihypertensive activities of Esmolol.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Olopatadine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Olopatadine.
Etacrynic acidOlopatadine may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Olopatadine.
EthanolOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Olopatadine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Olopatadine.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Olopatadine.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Olopatadine.
Ethyl biscoumacetateOlopatadine may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Olopatadine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Olopatadine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Olopatadine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Olopatadine.
Etidronic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etidronic acid.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Olopatadine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Olopatadine.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Olopatadine.
EtofenamateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etofenamate.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Olopatadine.
EtoperidoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etoperidone.
EtoricoxibThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etoricoxib.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Olopatadine.
EtravirineThe serum concentration of Olopatadine can be decreased when it is combined with Etravirine.
Evening primrose oilThe risk or severity of adverse effects can be increased when Olopatadine is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Olopatadine is combined with exisulind.
EzogabineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Felbamate.
FenbufenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fenbufen.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Olopatadine.
FenfluramineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fenfluramine.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Olopatadine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Olopatadine.
FexofenadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flibanserin.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Olopatadine.
FluconazoleThe metabolism of Olopatadine can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Olopatadine.
FlunarizineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Olopatadine.
FlunixinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flunixin.
FluoxetineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Olopatadine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Olopatadine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Olopatadine.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Olopatadine.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Olopatadine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Olopatadine.
FluvoxamineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluvoxamine.
FluvoxamineThe metabolism of Olopatadine can be decreased when combined with Fluvoxamine.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Olopatadine.
Fondaparinux sodiumOlopatadine may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Olopatadine.
FosamprenavirThe metabolism of Olopatadine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Olopatadine can be increased when it is combined with Fosaprepitant.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Olopatadine.
FosphenytoinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Olopatadine.
FramycetinOlopatadine may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideOlopatadine may decrease the diuretic activities of Furosemide.
Fusidic AcidThe serum concentration of Olopatadine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Olopatadine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Olopatadine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Olopatadine.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Olopatadine.
GentamicinOlopatadine may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Olopatadine.
GuanfacineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Olopatadine.
HaloperidolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Olopatadine.
HeparinOlopatadine may increase the anticoagulant activities of Heparin.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Olopatadine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Olopatadine.
HirulogOlopatadine may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Olopatadine is combined with HMPL-004.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Olopatadine.
HydralazineOlopatadine may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Olopatadine.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Olopatadine.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Olopatadine.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Olopatadine.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Olopatadine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.
HydroxyzineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Hydroxyzine.
Hygromycin BOlopatadine may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Olopatadine is combined with Icatibant.
IdarubicinOlopatadine may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IdelalisibThe serum concentration of Olopatadine can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Iloperidone.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Olopatadine.
ImatinibThe metabolism of Olopatadine can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Olopatadine.
IndalpineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Indalpine.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Olopatadine.
IndenololOlopatadine may decrease the antihypertensive activities of Indenolol.
IndinavirThe metabolism of Olopatadine can be decreased when combined with Indinavir.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Olopatadine.
IndoprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Olopatadine.
IsavuconazoniumThe metabolism of Olopatadine can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Olopatadine.
IsoxicamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Isoxicam.
IsradipineThe metabolism of Olopatadine can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Olopatadine can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Olopatadine can be increased when it is combined with Ivacaftor.
KanamycinOlopatadine may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Kebuzone.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Olopatadine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Olopatadine.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Olopatadine.
KetoconazoleThe metabolism of Olopatadine can be decreased when combined with Ketoconazole.
KetoprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Olopatadine.
LabetalolOlopatadine may decrease the antihypertensive activities of Labetalol.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Olopatadine.
LeflunomideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Leflunomide.
LepirudinOlopatadine may increase the anticoagulant activities of Lepirudin.
LevetiracetamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Levetiracetam.
LevobunololOlopatadine may decrease the antihypertensive activities of Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Olopatadine.
LevocabastineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Olopatadine is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Olopatadine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Olopatadine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Olopatadine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Olopatadine.
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Olopatadine.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Olopatadine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Olopatadine.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Olopatadine.
LopinavirThe metabolism of Olopatadine can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Olopatadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Olopatadine.
LornoxicamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Olopatadine.
LovastatinThe metabolism of Olopatadine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Olopatadine.
LoxoprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Loxoprofen.
Lu AA21004The risk or severity of adverse effects can be increased when Olopatadine is combined with Lu AA21004.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Olopatadine.
LuliconazoleThe serum concentration of Olopatadine can be increased when it is combined with Luliconazole.
LumiracoxibThe risk or severity of adverse effects can be increased when Olopatadine is combined with Lumiracoxib.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Olopatadine.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Magnesium salicylate.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Maprotiline.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Olopatadine.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Olopatadine.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Meclofenamic acid.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Olopatadine.
Mefenamic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mefenamic acid.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Olopatadine.
MeloxicamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Meloxicam.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Olopatadine.
MephentermineMephentermine may decrease the sedative activities of Olopatadine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Olopatadine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Olopatadine.
MesalazineOlopatadine may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Olopatadine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Olopatadine.
MetamizoleThe risk or severity of adverse effects can be increased when Olopatadine is combined with Metamizole.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Olopatadine.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Olopatadine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Olopatadine.
MethamphetamineMethamphetamine may decrease the sedative activities of Olopatadine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Olopatadine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Olopatadine.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Olopatadine.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Olopatadine.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Olopatadine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Olopatadine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Olopatadine.
MethsuximideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Methsuximide.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Olopatadine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Olopatadine.
MetipranololOlopatadine may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Olopatadine.
MetoprololOlopatadine may decrease the antihypertensive activities of Metoprolol.
MetrizamideOlopatadine may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MetyrosineOlopatadine may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Olopatadine.
MifepristoneThe metabolism of Olopatadine can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Olopatadine is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.
MirtazapineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Olopatadine.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Olopatadine.
MitotaneThe serum concentration of Olopatadine can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Olopatadine can be decreased when it is combined with Modafinil.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Olopatadine.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Olopatadine.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Olopatadine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Olopatadine.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Olopatadine.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mycophenolic acid.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.
NabiloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Nabilone.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Olopatadine.
NadololOlopatadine may decrease the antihypertensive activities of Nadolol.
NadroparinOlopatadine may increase the anticoagulant activities of Nadroparin.
NafcillinThe serum concentration of Olopatadine can be decreased when it is combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Olopatadine.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Olopatadine.
NaproxenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Naproxen.
NCX 4016The risk or severity of adverse effects can be increased when Olopatadine is combined with NCX 4016.
NefazodoneThe metabolism of Olopatadine can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Olopatadine can be decreased when combined with Nelfinavir.
NeomycinOlopatadine may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Olopatadine is combined with Nepafenac.
NetilmicinOlopatadine may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
NetupitantThe serum concentration of Olopatadine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Olopatadine can be decreased when combined with Nevirapine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Niflumic Acid.
NilotinibThe metabolism of Olopatadine can be decreased when combined with Nilotinib.
NimesulideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Nimesulide.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Olopatadine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Olopatadine.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Olopatadine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Olopatadine.
OlanzapineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Olanzapine.
OlaparibThe metabolism of Olopatadine can be decreased when combined with Olaparib.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Olopatadine.
OlsalazineOlopatadine may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Olopatadine.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Olopatadine.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Olopatadine.
OrgoteinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Orgotein.
OrphenadrineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Olopatadine.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Olopatadine.
OsimertinibThe serum concentration of Olopatadine can be increased when it is combined with Osimertinib.
OtamixabanOlopatadine may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Oxaprozin.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Olopatadine.
OxprenololOlopatadine may decrease the antihypertensive activities of Oxprenolol.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Olopatadine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Olopatadine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Olopatadine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Olopatadine.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Oxyphenbutazone.
PalbociclibThe serum concentration of Olopatadine can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Olopatadine.
PamidronateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pamidronate.
ParaldehydeOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Olopatadine.
ParecoxibThe risk or severity of adverse effects can be increased when Olopatadine is combined with Parecoxib.
ParomomycinOlopatadine may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
ParoxetineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Paroxetine.
PenbutololOlopatadine may decrease the antihypertensive activities of Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Olopatadine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Olopatadine.
Pentosan PolysulfateOlopatadine may increase the anticoagulant activities of Pentosan Polysulfate.
PerampanelThe risk or severity of adverse effects can be increased when Olopatadine is combined with Perampanel.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Olopatadine.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Olopatadine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Olopatadine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Olopatadine.
PhenindioneOlopatadine may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Olopatadine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Olopatadine.
PhenprocoumonOlopatadine may increase the anticoagulant activities of Phenprocoumon.
PhenterminePhentermine may decrease the sedative activities of Olopatadine.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Phenylbutazone.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Olopatadine.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Olopatadine.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Olopatadine.
PindololOlopatadine may decrease the antihypertensive activities of Pindolol.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Olopatadine.
PipotiazineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pipotiazine.
PiretanideOlopatadine may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Olopatadine.
PizotifenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pizotifen.
PlicamycinOlopatadine may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Olopatadine.
PomalidomideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pomalidomide.
PosaconazoleThe metabolism of Olopatadine can be decreased when combined with Posaconazole.
PractololOlopatadine may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Olopatadine.
PramipexoleOlopatadine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Olopatadine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Olopatadine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Olopatadine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Olopatadine.
PrimidoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Primidone.
ProbenecidThe serum concentration of Olopatadine can be increased when it is combined with Probenecid.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Olopatadine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Olopatadine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Olopatadine.
PromethazineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Promethazine.
PropacetamolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Propacetamol.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Olopatadine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Olopatadine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Olopatadine.
PropranololOlopatadine may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Olopatadine.
Protein COlopatadine may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeOlopatadine may increase the anticoagulant activities of Protocatechualdehyde.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Olopatadine.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Olopatadine.
PTC299The risk or severity of adverse effects can be increased when Olopatadine is combined with PTC299.
PuromycinOlopatadine may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Olopatadine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Olopatadine.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Olopatadine.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Olopatadine.
RamelteonThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ramelteon.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Olopatadine.
RanolazineThe metabolism of Olopatadine can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Olopatadine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Olopatadine.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Olopatadine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Olopatadine.
ResveratrolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Resveratrol.
ReviparinOlopatadine may increase the anticoagulant activities of Reviparin.
RibostamycinOlopatadine may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RifabutinThe metabolism of Olopatadine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Olopatadine can be increased when combined with Rifampicin.
RifapentineThe metabolism of Olopatadine can be increased when combined with Rifapentine.
RisedronateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Risedronate.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Olopatadine.
RitonavirThe metabolism of Olopatadine can be decreased when combined with Ritonavir.
RivaroxabanOlopatadine may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Olopatadine.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Olopatadine.
RopiniroleOlopatadine may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Olopatadine.
RotigotineOlopatadine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Olopatadine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Olopatadine.
SalicylamideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Salicylic acid.
SalsalateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Salsalate.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Olopatadine.
SaquinavirThe metabolism of Olopatadine can be decreased when combined with Saquinavir.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Olopatadine.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Olopatadine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Olopatadine.
SeratrodastThe risk or severity of adverse effects can be increased when Olopatadine is combined with Seratrodast.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Olopatadine.
SertralineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Olopatadine.
SildenafilThe metabolism of Olopatadine can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Olopatadine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Olopatadine can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Olopatadine.
SotalolOlopatadine may decrease the antihypertensive activities of Sotalol.
SpectinomycinOlopatadine may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Olopatadine.
SpironolactoneOlopatadine may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Olopatadine is combined with SRT501.
St. John's WortThe serum concentration of Olopatadine can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Stiripentol.
StreptomycinOlopatadine may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinOlopatadine may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Olopatadine.
SulfasalazineOlopatadine may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Olopatadine.
SulfisoxazoleThe metabolism of Olopatadine can be decreased when combined with Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Olopatadine.
SulodexideOlopatadine may increase the anticoagulant activities of Sulodexide.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Olopatadine.
SuprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Suprofen.
SuvorexantThe risk or severity of adverse effects can be increased when Olopatadine is combined with Suvorexant.
TacrolimusOlopatadine may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Olopatadine.
TapentadolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tasimelteon.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Olopatadine.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Technetium Tc-99m Medronate.
TelaprevirThe metabolism of Olopatadine can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Olopatadine can be decreased when combined with Telithromycin.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Olopatadine.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Olopatadine.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Olopatadine.
TenofovirThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Olopatadine.
TepoxalinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Olopatadine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Olopatadine.
ThalidomideOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Olopatadine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Olopatadine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Olopatadine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Olopatadine.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Olopatadine.
TiagabineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tiagabine.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tiaprofenic acid.
TiclopidineThe metabolism of Olopatadine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Olopatadine.
TiludronateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tiludronate.
TimololOlopatadine may decrease the antihypertensive activities of Timolol.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Olopatadine.
TobramycinOlopatadine may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TocilizumabThe serum concentration of Olopatadine can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Olopatadine.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Olopatadine.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Olopatadine.
TorasemideOlopatadine may decrease the diuretic activities of Torasemide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Olopatadine.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Olopatadine.
TranilastThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tranilast.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Olopatadine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Olopatadine.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Olopatadine.
TrazodoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Trazodone.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Olopatadine.
TriamtereneOlopatadine may decrease the antihypertensive activities of Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Olopatadine.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Olopatadine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Olopatadine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Olopatadine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Olopatadine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Olopatadine.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Trisalicylate-choline.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Olopatadine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Olopatadine.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Olopatadine.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Olopatadine.
VenlafaxineThe metabolism of Olopatadine can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Olopatadine can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Vilazodone.
VoriconazoleThe metabolism of Olopatadine can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Vortioxetine.
WarfarinOlopatadine may increase the anticoagulant activities of Warfarin.
XimelagatranOlopatadine may increase the anticoagulant activities of Ximelagatran.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Olopatadine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Olopatadine.
ZaltoprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zaltoprofen.
ZiconotideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ziconotide.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Olopatadine.
ZimelidineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zimelidine.
ZiprasidoneThe metabolism of Olopatadine can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Olopatadine.
Zoledronic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zoledronic acid.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Olopatadine.
ZomepiracThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zomepirac.
ZonisamideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Olopatadine.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Olopatadine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Olopatadine.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Tamura T, Masaki S, Ohmori K, Karasawa A: Effect of olopatadine and other histamine H1 receptor antagonists on the skin inflammation induced by repeated topical application of oxazolone in mice. Pharmacology. 2005 Dec;75(1):45-52. Epub 2005 Jun 7. [PubMed:15942272 ]
  2. Ohmori K, Hayashi K, Kaise T, Ohshima E, Kobayashi S, Yamazaki T, Mukouyama A: Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol. 2002 Apr;88(4):379-97. [PubMed:12046981 ]
  3. Yanni JM, Stephens DJ, Miller ST, Weimer LK, Graff G, Parnell D, Lang LS, Spellman JM, Brady MT, Gamache DA: The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther. 1996 Winter;12(4):389-400. [PubMed:8951675 ]
  4. Ohmori K, Hasegawa K, Tamura T, Miyake K, Matsubara M, Masaki S, Karasawa A, Urayama N, Horikoshi K, Kajita J, Hasegawa M, Taniguchi K, Komada T, Kawamoto Y: Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug. Arzneimittelforschung. 2004;54(12):809-29. [PubMed:15646365 ]
  5. Ohmori K, Ikemura T, Kobayashi H, Mukouyama A: [Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride' (olopatadine), an antiallergic drug]. Nihon Yakurigaku Zasshi. 2001 Jul;118(1):51-8. [PubMed:11496828 ]
  6. Roland PS, Ryan MW, Wall GM: Olopatadine nasal spray for the treatment of seasonal allergic rhinitis in patients aged 6 years and older. Expert Opin Pharmacother. 2010 Jun;11(9):1559-67. doi: 10.1517/14656566.2010.485609. [PubMed:20482305 ]
  7. Kaliner MA, Oppenheimer J, Farrar JR: Comprehensive review of olopatadine: the molecule and its clinical entities. Allergy Asthma Proc. 2010 Mar-Apr;31(2):112-9. doi: 10.2500/aap.2010.31.3317. [PubMed:20406593 ]
  8. Roland PS, Marple BF, Wall GM: Olopatadine nasal spray for the treatment of allergic rhinitis. Expert Rev Clin Immunol. 2010 Mar;6(2):197-204. [PubMed:20402382 ]
  9. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
S100 protein binding
Specific Function:
Weakly binds calcium but binds zinc very tightly-distinct binding sites with different affinities exist for both ions on each monomer. Physiological concentrations of potassium ion antagonize the binding of both divalent cations, especially affecting high-affinity calcium-binding sites. May mediate calcium-dependent regulation on many physiological processes by interacting with other proteins, ...
Gene Name:
S100A1
Uniprot ID:
P23297
Molecular Weight:
10545.755 Da
References
  1. Okada M, Tokumitsu H, Kubota Y, Kobayashi R: Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochem Biophys Res Commun. 2002 Apr 12;292(4):1023-30. [PubMed:11944917 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
S100A12 is a calcium-, zinc- and copper-binding protein which plays a prominent role in the regulation of inflammatory processes and immune response. Its proinflammatory activity involves recruitment of leukocytes, promotion of cytokine and chemokine production, and regulation of leukocyte adhesion and migration. Acts as an alarmin or a danger associated molecular pattern (DAMP) molecule and st...
Gene Name:
S100A12
Uniprot ID:
P80511
Molecular Weight:
10574.975 Da
References
  1. Kishimoto K, Kaneko S, Ohmori K, Tamura T, Hasegawa K: Olopatadine suppresses the migration of THP-1 monocytes induced by S100A12 protein. Mediators Inflamm. 2006;2006(1):42726. [PubMed:16864903 ]
  2. Okada M, Tokumitsu H, Kubota Y, Kobayashi R: Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochem Biophys Res Commun. 2002 Apr 12;292(4):1023-30. [PubMed:11944917 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Zinc ion binding
Specific Function:
Weakly binds calcium but binds zinc very tightly-distinct binding sites with different affinities exist for both ions on each monomer. Physiological concentrations of potassium ion antagonize the binding of both divalent cations, especially affecting high-affinity calcium-binding sites. Binds to and initiates the activation of STK38 by releasing autoinhibitory intramolecular interactions within...
Gene Name:
S100B
Uniprot ID:
P04271
Molecular Weight:
10712.985 Da
References
  1. Okada M, Tokumitsu H, Kubota Y, Kobayashi R: Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochem Biophys Res Commun. 2002 Apr 12;292(4):1023-30. [PubMed:11944917 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Zinc ion binding
Specific Function:
Plays a role in the export of proteins that lack a signal peptide and are secreted by an alternative pathway. Binds two calcium ions per subunit. Binds one copper ion. Binding of one copper ion does not interfere with calcium binding. Required for the copper-dependent stress-induced export of IL1A and FGF1. The calcium-free protein binds to lipid vesicles containing phosphatidylserine, but not ...
Gene Name:
S100A13
Uniprot ID:
Q99584
Molecular Weight:
11471.095 Da
References
  1. Okada M, Tokumitsu H, Kubota Y, Kobayashi R: Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochem Biophys Res Commun. 2002 Apr 12;292(4):1023-30. [PubMed:11944917 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Identical protein binding
Specific Function:
May function as calcium sensor and modulator, contributing to cellular calcium signaling. May function by interacting with other proteins, such as TPR-containing proteins, and indirectly play a role in many physiological processes. May also play a role in suppressing tumor cell growth.
Gene Name:
S100A2
Uniprot ID:
P29034
Molecular Weight:
11116.695 Da
References
  1. Okada M, Tokumitsu H, Kubota Y, Kobayashi R: Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochem Biophys Res Commun. 2002 Apr 12;292(4):1023-30. [PubMed:11944917 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 28, 2016 03:41